Targeting cytokine and chemokine signaling pathways for cancer therapy

M Yi, T Li, M Niu, H Zhang, Y Wu, K Wu… - Signal transduction and …, 2024 - nature.com
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …

FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions

M Katoh, Y Loriot, G Brandi, S Tavolari… - Nature Reviews …, 2024 - nature.com
Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma

Q Wu, H Ellis, G Siravegna, AG Michel, BL Norden… - Clinical Cancer …, 2024 - AACR
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to
approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible …

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

F Facchinetti, Y Loriot, F Brayé, D Vasseur… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …

Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment

Z Wang, F Miao, L Gu, R Zhang, Y Ma, Y Li, J Zheng… - ACS …, 2024 - ACS Publications
Fibrosarcoma, a malignant mesenchymal tumor, is characterized by aggressive
invasiveness and a high recurrence rate, leading to poor prognosis. Anthracycline drugs …

New clinical trial design in precision medicine: discovery, development and direction

XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially …

MF Sabbagh, T Janovitz, D Dias-Santagata… - Thyroid, 2024 - liebertpub.com
Background: Diagnostic classification of thyroid malignancy is primarily accomplished
through examination of histomorphological features and may be substantiated and clarified …

Molecular profiling and targeted therapies in gliomas

Y Felistia, PY Wen - Current Neurology and Neuroscience Reports, 2023 - Springer
Abstract Purpose of Review Molecular profiling enables the evaluation of genetic alterations
for the diagnosis and classification of gliomas and the selection of appropriate therapies …

[HTML][HTML] Empowering effective biomarker-driven precision oncology: A call to action

M Lawler, P Keeling, O Kholmanskikh… - European Journal of …, 2024 - Elsevier
Precision oncology has a significant role to play in delivering optimal patient care.
Biomarkers are critical enablers for precision oncology across the continuum of cancer …

Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma

A Lamarca, L Ostios, MG McNamara, C Garzon… - Cancer Treatment …, 2023 - Elsevier
Precision medicine is a major achievement that has impacted on management of patients
diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular …